New Parkinson's drug buntanetap tested for long-term safety in 500 patients
Disease control
Recruiting now
This study looks at the long-term safety of the drug buntanetap in 500 people with Parkinson's disease over 36 months. It includes two groups: those who have taken buntanetap before and those who have a deep brain stimulation device. Participants take one 30 mg pill daily, and re…
Phase: PHASE2, PHASE3 • Sponsor: Annovis Bio Inc. • Aim: Disease control
Last updated May 26, 2026 08:35 UTC